ABOUT ONCOSENX
OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique Proteo-Lipid Vehicle (PLV) and plasmid DNA.
OUR MISSION
The next generation in cancer therapies will be more targeted with less side effects. At OncoSenX we believe the battle against cancer should be fought with genetic information. Our treatment delivers a simple program that induces apoptosis in cancerous cells. Our approach is a less invasive, more precise intervention for this complex and devastating disease. The next generation of cancer therapies has begun...
SCIENCE
OUR SYSTEM
Our system is comprised of two main components: An untargeted non-toxic Proteo-Lipid Vehicle (PLV) and a highly targeted DNA payload.
CELL TARGETING
DNA plasmids encode an inducible death protein under a promoter that is active in the target cell population. We are initially targeting cells that are transcriptionally active for p53.
Cells are killed via apoptosis with caspase 9.
We can use our DNA payload to effectively implement logic gates (IF/OR/AND). This allows us to precisely target cell populations based on their genetic activity without harming adjacent cells.
DELIVERY
Our patented Proteo-Lipid Vehicle (PLV) is the transfection agent that efficiently delivers our non-integrating DNA plasmid to cancer cells
These PLVs have been shown to be non-immunogenic, even with adjuvant, and are non-toxic at doses up to 10x expected human therapeutic dose in rodents and non-human primates.
SAFETY
Anti-PLV antibody & neutralization assays:
Virtually no antibody response to PLVs in immune-competent mice, even with adjuvants
Neutralization requires very high antibody concentration
“Vaccination” against PLVs does not reduce efficacy
Repeat dosing is effective and well tolerated
CARPA Assays
PLVs are generally less reactive than other lipid drug formulations
Our Partners
TEAM
Keep up with the latest about OncoSenx
Articles
Videos
OncoSenX 3 Minute Intro
December, 2020
OncoSenX targeting solid tumors with its unique technology
Proactive | January 14, 2020
ARM Cell and Gene Therapy Meeting on the Mesa (Matt Scholz)
October 3, 2019
CORPORATE HEADQUARTERS
701 Fifth Ave, Suite 4200
Seattle, Washington 98104
INQUIRIES